



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Continue to promote the responsible use of antimicrobials and their alternatives

Feedback from breakout session 3A

EMA's Regulatory Science Strategy to 2025 – Veterinary Stakeholder Workshop

Presented by Christine Schwarz, AMR Working Party - Thomas Heberer, BVL on 5 December 2019
Supported by Helen Jukes, Javier Pozo Gonzalez, EMA



An agency of the European Union





Disclaimer



Comments to the underlying actions represent the views of stakeholders and not the European Medicines Agency.

The fact that these comments from stakeholders are displayed in the presentation does not mean we endorse them or commit to fulfil them in any way.



High level actions & feedback




Continued access to established products

- All agreed that old antimicrobials must be kept on the market
- New (clinical) data will be difficult to generate
- Use of modelling methods is supported: Expertise available at VetCAST
- Paucity of data in old dossiers
- Risk of loss of products from the market
- Bottom line for supporting old AMs is return on investment: competing against novel products and ATAs for pharma investment



High level actions & feedback




Reserved List

- Cascade is essential for vets in practice
- List is a disincentive for development of new AMs in case they are put on the list – ‘regulatory uncertainty’
- If MSs place further restrictions at national level this will invalidate the EU list
- Need to consider risk of zoonotic infections (pets) if they cannot be treated
- Truly novel human AMs to be reserved for humans only?
- EMA Open Call for information on Cascade use to open shortly



High level actions & feedback



Diagnostic test

- No harmonised EU regulation
- Diagnostic tests available now may be too costly, too slow and inaccurate
- Divergent views over who is responsible for developing diagnostic tests

High level actions & feedback



Alternatives to Antibiotics

- Lack of consistent terminology and uncertainty on classification, need for MRLs
- Limitation of CVMP reflection paper: scope for veterinary medicinal products only
- Issue/risk of presence of unregulated products on the market
- Claims: value of giving information in the SPC on the effect in reducing antimicrobial use, even if not a claim; but need to define main claims; descriptive claims?
- Importance of patent protection (patents only for novel substances)
- Difficulty in identifying the most promising alternative products during development
- Industry ready to start discussions with EMA

Roadmap of actions/deliverables



- New funding models needed for data to maintain old products (PKPD, new clinical data) and establishing break-points e.g. EU project, public funding
- Incentivise MAHs to maintain old AMs e.g. offer fast track authorisation of an ATAb
- Message needed from Regulators: novel vet AMs will not automatically be reserved
- Route to bring back old AMs
- Effectiveness of substances on the reserved list in humans needs to be monitored
- Regulation of diagnostic kits is essential and should be harmonised across EU
- Global leadership needed on AMR - AM in the Environment needs to be addressed
- ATAbs – develop EU position first; then global alignment for GLs



Any questions?

Further information

RegulatoryScience2025@ema.europa.eu

Temporary visiting address Spark building • Orlyplein 24 • 1043 DP Amsterdam • The Netherlands
For deliveries refer to www.ema.europa.eu/how-to-find-us

Send us a question via www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

Follow us on  **@EMA_News**



#RegScience2025